Cargando…

The prevalence of intestinal dysbiosis in patients referred for antireflux surgery

BACKGROUND: Prior to antireflux surgery, most patients with symptoms of gastroesophageal reflux disease (GERD) have been taking long-term proton pump inhibitors (PPIs). PPIs have been shown to cause changes to the intestinal microbiota, such as small intestinal bacterial overgrowth (SIBO), which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Haworth, Jordan J., Boyle, Nicholas, Vales, Andres, Hobson, Anthony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599257/
https://www.ncbi.nlm.nih.gov/pubmed/33475845
http://dx.doi.org/10.1007/s00464-020-08229-5
_version_ 1784600909362233344
author Haworth, Jordan J.
Boyle, Nicholas
Vales, Andres
Hobson, Anthony R.
author_facet Haworth, Jordan J.
Boyle, Nicholas
Vales, Andres
Hobson, Anthony R.
author_sort Haworth, Jordan J.
collection PubMed
description BACKGROUND: Prior to antireflux surgery, most patients with symptoms of gastroesophageal reflux disease (GERD) have been taking long-term proton pump inhibitors (PPIs). PPIs have been shown to cause changes to the intestinal microbiota, such as small intestinal bacterial overgrowth (SIBO), which is characterised by symptoms of gas bloating. Patients undergoing antireflux surgery are not routinely screened for SIBO, yet many patients experience gas-related symptoms postoperatively. METHODS: Data from consecutive patients (n = 104) referred to a speciality reflux centre were retrospectively assessed. Patients underwent a routine diagnostic workup for GERD including history, endoscopy, oesophageal manometry and 24-h pH-impedance monitoring off PPIs. Intestinal dysbiosis was determined by hydrogen and methane breath testing with a hydrogen-positive result indicative of SIBO and a methane-positive result indicative of intestinal methanogen overgrowth (IMO). RESULTS: 60.6% of patients had intestinal dysbiosis (39.4% had SIBO and 35.6% had IMO). Patients with dysbiosis were more likely to report bloating (74.6% vs 48.8%; P = 0.01) and belching (60.3% vs 34.1%; P = 0.01). The oesophageal acid exposure time and number of reflux episodes were similar between dysbiosis and non-dysbiosis groups, but patients with dysbiosis were more likely to have a positive reflux-symptom association (76.2% vs 31.7%; P < 0.001), especially for regurgitation in those with SIBO (P = 0.01). Hydrogen gas production was significantly greater in patients with a positive reflux-symptom association for regurgitation (228.8 ppm vs 129.1 ppm, P = 0.004) and belching (mean AUC 214.8 ppm vs 135.9 ppm, P = 0.02). CONCLUSIONS: The prevalence of intestinal dysbiosis is high in patients with GERD, and these patients are more likely to report gas-related symptoms prior to antireflux surgery. Independently, SIBO may be a contributory factor to refractory reflux symptoms and gas bloating in antireflux surgery candidates.
format Online
Article
Text
id pubmed-8599257
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-85992572021-11-24 The prevalence of intestinal dysbiosis in patients referred for antireflux surgery Haworth, Jordan J. Boyle, Nicholas Vales, Andres Hobson, Anthony R. Surg Endosc Article BACKGROUND: Prior to antireflux surgery, most patients with symptoms of gastroesophageal reflux disease (GERD) have been taking long-term proton pump inhibitors (PPIs). PPIs have been shown to cause changes to the intestinal microbiota, such as small intestinal bacterial overgrowth (SIBO), which is characterised by symptoms of gas bloating. Patients undergoing antireflux surgery are not routinely screened for SIBO, yet many patients experience gas-related symptoms postoperatively. METHODS: Data from consecutive patients (n = 104) referred to a speciality reflux centre were retrospectively assessed. Patients underwent a routine diagnostic workup for GERD including history, endoscopy, oesophageal manometry and 24-h pH-impedance monitoring off PPIs. Intestinal dysbiosis was determined by hydrogen and methane breath testing with a hydrogen-positive result indicative of SIBO and a methane-positive result indicative of intestinal methanogen overgrowth (IMO). RESULTS: 60.6% of patients had intestinal dysbiosis (39.4% had SIBO and 35.6% had IMO). Patients with dysbiosis were more likely to report bloating (74.6% vs 48.8%; P = 0.01) and belching (60.3% vs 34.1%; P = 0.01). The oesophageal acid exposure time and number of reflux episodes were similar between dysbiosis and non-dysbiosis groups, but patients with dysbiosis were more likely to have a positive reflux-symptom association (76.2% vs 31.7%; P < 0.001), especially for regurgitation in those with SIBO (P = 0.01). Hydrogen gas production was significantly greater in patients with a positive reflux-symptom association for regurgitation (228.8 ppm vs 129.1 ppm, P = 0.004) and belching (mean AUC 214.8 ppm vs 135.9 ppm, P = 0.02). CONCLUSIONS: The prevalence of intestinal dysbiosis is high in patients with GERD, and these patients are more likely to report gas-related symptoms prior to antireflux surgery. Independently, SIBO may be a contributory factor to refractory reflux symptoms and gas bloating in antireflux surgery candidates. Springer US 2021-01-21 2021 /pmc/articles/PMC8599257/ /pubmed/33475845 http://dx.doi.org/10.1007/s00464-020-08229-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Haworth, Jordan J.
Boyle, Nicholas
Vales, Andres
Hobson, Anthony R.
The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title_full The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title_fullStr The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title_full_unstemmed The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title_short The prevalence of intestinal dysbiosis in patients referred for antireflux surgery
title_sort prevalence of intestinal dysbiosis in patients referred for antireflux surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599257/
https://www.ncbi.nlm.nih.gov/pubmed/33475845
http://dx.doi.org/10.1007/s00464-020-08229-5
work_keys_str_mv AT haworthjordanj theprevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT boylenicholas theprevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT valesandres theprevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT hobsonanthonyr theprevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT haworthjordanj prevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT boylenicholas prevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT valesandres prevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery
AT hobsonanthonyr prevalenceofintestinaldysbiosisinpatientsreferredforantirefluxsurgery